ICML 2023: Focus on CLL
Zanubrutinib monotherapy was shown to have favorable toxicity compared with ibrutinib in patients with B-cell malignancies.
Switching from VR-EPOCH to VR-CHOP reduced toxicities while maintaining efficacy in patients with CLL and Richter's syndrome.
Acalabrutinib had safety outcomes consistent with the general population even for very old or frail patients with CLL.
Adjusting ibrutinib dosage after a cardiac adverse event in the first year of treatment reduced the risk of recurrence.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.